Back to medical news
MedPage Today
Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia
October 2, 2026
Original source summary
(MedPage Today) -- The FDA on Friday expanded the approval of pirtobrutinib (Jaypirca) in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) to include the first-line treatment of adults whose cancers have no known 17p deletion...
Verbatim from MedPage Today's own feed — "Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia"
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news